Notice of Proposed Sale · 144
Biogen Inc.
BIIBNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- BIOGEN INC.
- Issuer CIK
- 0000875045
- SEC file number
- 000-19311
- Phone
- 6176792000
- Person for whose account securities are to be sold
- Minor Lloyd
- Relationships to issuer
- Director
- Street
- 225 BINNEY STREET
- City
- CAMBRIDGE
- State / country code
- MA
- Postal code
- 02142
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 593 | 119,169.28 | 147,753,998 | 08/04/2026 | NASDAQ | Fidelity Brokerage Services LLC |
Broker / market maker — proposed row 1, entry 1
- Name
- Fidelity Brokerage Services LLC
- Street
- 900 Salem Street
- City
- Smithfield
- State / country code
- RI
- Postal code
- 02917
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 06/09/2026 | Restricted Stock Vesting | Issuer | 593 | N | 06/09/2026 | Compensation |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| Lloyd Minor | Common | 08/03/2026 | 593 | 120,580.62 |
Seller — prior-sale row 1, entry 1
- Name
- Lloyd Minor
- Street
- 225 Binney Street
- City
- Cambridge
- State / country code
- MA
- Postal code
- 02142
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Notice signature
- Notice date
- 08/04/2026
- Signed
- /s/ Daniel Tucci, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Lloyd Minor
- Plan adoption dates
- 05/04/2026
Company context
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth. We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media - Facebook, Instagram, LinkedIn, X, YouTube.